250
Participants
Start Date
February 27, 2018
Primary Completion Date
April 18, 2022
Study Completion Date
September 1, 2026
MMprofiler SKY92 gene signature
"MMprofiler is a gene expression assay system for detection of the presence (or absence) of the SKY92 high-risk gene signature to aid in the determination of the Multiple Myeloma patient's prognosis"
Columbia University Medical Center, New York
Weill Cornell Medicine, New York
New York Presbyterian Brooklyn Methodist Hospital, Brooklyn
Lombardi Comprehensive Cancer Center, Washington D.C.
Wake Forest Baptist Medical Center,, Winston-Salem
Levine Cancer Institute, Charlotte
Winship Cancer Institute, Emory University, Atlanta
Medical College of Wisconsin, Milwaukee
Hackensack University Medical Center, Hackensack